NCT05448391

A Study to Evaluate RIST4721 in Familial Mediterranean Fever (FMF)

An Open-label, Single-arm, Phase 2 Study to Evaluate the Safety and Efficacy of RIST4721 in Subjects With Familial Mediterranean Fever

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Aristea Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years – 74 Years
• Healthy volunteers: Not accepted

Summary

A 12-week Open-label, Single-arm, Phase 2 Study to Evaluate the Safety and Efficacy of RIST4721 in Subjects with Familial Mediterranean Fever followed by an additional Open-label Extension Phase.

Conditions

• Familial Mediterranean Fever

Interventions

Type	Name	Description
DRUG	RIST4721	RIST4721 tablets, 100 mg are blue, oval, biconvex film-coated tablets

Timeline

• Start date: 2022-09-13
• Primary completion: 2023-11-30
• Completion: 2024-12-30
• First posted: 2022-07-07
• Last updated: 2023-02-13

Regulatory

• FDA-regulated drug study